New bill would require details on doc payments

The brouhaha over pharmaceutical companies' payments to doctors is making some big waves in Congress. Sen. Charles Grassley (R-IA) says he's going to propose a bill that would require drug makers to 'fess up to any payments for consulting, lectures, and the like. Pharma, of course, is against the measure; a drug company lawyer said that making the cash flow public would lay the money bare to misinterpretation: People might think the payments are bribes, when they're just remuneration for services rendered. Besides, the poor doctors might be too embarrassed to attend those money-for-attendance seminars, thus neglecting their education.

- read the article on the bill from The New York Times

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.